

FIG. 1.





FIG. 2.



- Onconase, Daudi
- Onconase, CA-46
- LL2-Onconase, Daudi
- LL2-Onconase, CA-46

FIG. 3.







FIG. 4.

**The Effect of LL2-Onc vs LL2-hPanc on  
Daudi Lymphoma cells**



## % Retained on Daudi Cells



**% Degraded**





FIG. 6.



7/9

MPT Daudi/i.v. in SCID mice, I20996






FIG. 7.

FIG. 8.



204010-208100

FIG. 9.



- LL2-Onc, 300 mg/kg
- Onc, 25 mg/kg
- Onc, 30 mg/kg
- PBS
- IT-dgRTA, 50 mg/kg

Drugs administered every 2 h  
4x/day for 5 days. The arrows  
indicate the days the mice with  
each respective treatment were  
found dead.

RFB4-PE35KDEL, 1 x/day for 4 days: LD50 1 mg/kg